Literature DB >> 15345300

The methodology for determining the efficacy of antibody-mediated immunity.

Arturo Casadevall1.   

Abstract

The basic method for evaluating the efficacy of antibody-mediated immunity (AMI) dates from the 1890s and involves the administration of specific Ab to an immunologically naïve host followed by microbial or toxin challenge. Other methods used to evaluate AMI involve correlating the presence of specific Ab with resistance to microbial disease and associating susceptibility to certain microbes with host immunoglobulin deficits. Unfortunately, each method has theoretical and practical problems that limit their usefulness when negative results are obtained. The application of hybridoma technology to investigate the efficacy of AMI has shown that it is possible to generate protective monoclonal antibodies even to microbes for which the standard methodologies indicate no role for AMI. Furthermore, studies with monoclonal antibodies suggest various explanations for the inability of standard methods to demonstrate the potential efficacy of AMI for certain pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15345300     DOI: 10.1016/j.jim.2004.04.027

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

Review 1.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

2.  Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.

Authors:  Ying Peng; Laura Schoenlaub; Alexandra Elliott; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

Review 3.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

4.  Dependence of macrophage phagocytic efficacy on antibody concentration.

Authors:  Natasa Macura; Tong Zhang; Arturo Casadevall
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

5.  Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites.

Authors:  Nahiara Esteves Zorgi; Andrés Jimenez Galisteo; Maria Notomi Sato; Nanci do Nascimento; Heitor Franco de Andrade
Journal:  Med Microbiol Immunol       Date:  2016-01-05       Impact factor: 3.402

6.  Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.

Authors:  Avanish K Varshney; Xiaobo Wang; Matthew D Scharff; Jennifer MacIntyre; Richard S Zollner; Oleg V Kovalenko; Luis R Martinez; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

Review 7.  Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

Review 8.  B cell TLRs and induction of immunoglobulin class-switch DNA recombination.

Authors:  Egest J Pone; Zhenming Xu; Clayton A White; Hong Zan; Paolo Casali
Journal:  Front Biosci (Landmark Ed)       Date:  2012-06-01

Review 9.  Vaccines Through Centuries: Major Cornerstones of Global Health.

Authors:  Inaya Hajj Hussein; Nour Chams; Sana Chams; Skye El Sayegh; Reina Badran; Mohamad Raad; Alice Gerges-Geagea; Angelo Leone; Abdo Jurjus
Journal:  Front Public Health       Date:  2015-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.